Guardant Health Inc (GH) - News Archive

Guardant Health Inc has recently emerged as a compelling investment option due to its positive technical indicators, strong insider ownership, and impressive market performance. With a recent golden cross event and a no...

Guardant Health: A Leader in Precision Oncology Recognized as One of the TIME100 Most Influential CompaniesPalo Alto, California - Guardant Health, Inc. (NASDAQ:GH), a prominent precision oncology company, has been hono...

Guardant Health s Shield Blood Test Receives Strong FDA Committee Recommendation for Colorectal Cancer ScreeningPALO ALTO, Calif. - In a groundbreaking development for cancer screening, Guardant Health, a leading precis...

Extensive Guardant Health Temporarily Halted, FDA Panel Reviewing Blood Test for Colorectal Cancer ScreeningPalo Alto-based precision oncology company, Guardant Health Inc. (Nasdaq: GH), has recently made two important...

Guardant Health Enhances Employee Incentives Through Targeted Equity Grants In a move underscoring its commitment to aligning employee interests with shareholder value, Guardant Health, Inc. (Nasdaq: GH), a prominent pl...

Guardant Health, a renowned precision oncology company, has recently made significant strides in bolstering its workforce by announcing inducement grants for new non-executive employees. These grants include restricted...

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif. - Guardant Health, Inc. (Nasdaq: GH), a pioneering firm in precision oncology, has disclosed impressive developments in...

Guardant Health to Present Real-World Data Supporting Performance of Shield Blood Test for Colorectal Cancer Screening at 2024 Digestive Disease WeekPalo Alto, California - Guardant Health, Inc. (Nasdaq: GH), a leading...

Guardant Health Reports Strong Financial Results and Achieves Milestones in Precision Oncology ResearchGuardant Health, a leading precision oncology company, has announced its financial results for the first quarter of...

PALO ALTO, Calif. In the rapidly evolving world of precision oncology, Guardant Health, Inc. (Nasdaq: GH), a leading industry player, posted impressive Q1 2024 financial results recently. The company reported a revenue...

Guardant Health, the Palo Alto-based company breaking new ground in precision oncology, recently achieved a remarkable milestone of being featured in 500 peer-reviewed publications in esteemed scientific journals. Such...

In a significant development for the fight against colorectal cancer (CRC), Guardant Health, Inc. has announced that its Shield blood test will undergo review by the Molecular and Clinical Genetics Panel of the U.S. Foo...